Company: RNAC
Filing Date: 2025-01-08
Form Type: 424B7
Source: 0001140361-25-000631
Chunk: 10

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-01-08
Form: 424B7
Chunk 10
---
30, 2024, at a weighted average exercise price of $46.04 per share; |

| • | 3,511,101 shares of Common Stock reserved for issuance as of September 30, 2024 under the 2016 Incentive Award Plan; |

| • | 27,270 shares of Common Stock reserved for issuance as of September 30, 2024 under the 2016 Stock Incentive Plan; |

| • | 253,377 shares of Common Stock reserved for issuance as of September 30, 2024 under the Inducement Plan; and |

| • | 45,795 shares of Common Stock reserved for issuance as of September 30, 2024 pursuant to our 2016 Employee Stock Purchase Plan. |

For additional information concerning the offering, see the section titled “ Plan of Distribution.”

8

#### TABLE OF CONTENTS

### RISK FACTORS
Investing in securities issued by us involves a high degree of risk. Before deciding whether to invest in our securities, you should consider carefully the risks described under the heading “ Risk Factors ” in any of our filings with the SEC that are incorporated by reference herein.

<div align='center'>9</div>

#### TABLE OF CONTENTS

### USE OF PROCEEDS
We are not selling any securities under this prospectus and we will not receive any proceeds from the sale of the Resale Shares covered hereby. The net proceeds from the sale of the Resale Shares offered by this prospectus will be received by the Selling Stockholders.

Subject to limited exceptions, the Selling Stockholders will pay any underwriting discounts and commissions and expenses incurred by the Selling Stockholders for brokerage, accounting, tax or legal services or any other expenses incurred by the Selling Stockholders in disposing of any of the Resale Shares. We will bear the costs, fees and expenses incurred in effecting the registration of the Resale Shares covered by this prospectus, including all registration and filing fees, listing fees of the Nasdaq Stock Market LLC and fees and expenses of our counsel and our independent registered public accounting firm.

<div align='center'>10</div>

#### TABLE OF CONTENTS

### DESCRIPTION OF CAPITAL STOCK
The following description of our capital stock is not complete and may not contain all the information you should consider before investing in our capital stock. This description is summarized from, and qualified in its entirety by reference to, our restated certificate of incorporation, as amended, or the Charter, our amended and restated by-l